Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 11/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964374 | 0.94 | ADRB1 (0.49) | ADRB3ADRB1ADRB2PLA2G1BPOLB | |
| SCHEMBL5963803 | 0.86 | FAAH (0.45) | ADRB3ADRB1ADRB2RORC | |
| SCHEMBL5964011 | 0.83 | ADRB3 (0.69) | ADRB3ADRB1ADRB2PLA2G1BPOLB | |
| SCHEMBL5964593 | 0.78 | KMT2A (0.52) | ADRB3ADRB1ADRB2GAASMN1; SMN2 | |
| SCHEMBL6211713 | 0.77 | ADRB3 (0.66) | ADRB3ADRB1ADRB2PLA2G1BPOLB | |
| SCHEMBL5964266 | 0.76 | CNR2 (0.71) | PLA2G1BPOLBATG4BRORCKDM4E | |
| SCHEMBL5964296 | 0.75 | ADRB3 (0.52) | ADRB3ADRB1ADRB2PLA2G1BPOLB | |
| SCHEMBL5964346 | 0.74 | ADRB2 (0.53) | ADRB3ADRB1ADRB2GAASMN1; SMN2 | |
| SCHEMBL5964330 | 0.74 | ADRB2 (0.61) | ADRB3ADRB1ADRB2KDM4EGAA | |
| SCHEMBL5964586 | 0.74 | FAAH (0.45) | ADRB3ADRB1ADRB2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1594856-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004060882-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | ADRB3 86/4885ADRB1 23/4885ADRB2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.